Clinical Trial Update: Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating magrolimab (Hu5F9-G4) with avelumab in solid tumors and checkpoint-inhibitor-naive ovarian cancer patients who progressed after platinu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avelumab (avelumab)
• Magrolimab (Hu5F9-G4) (magrolimab)

Snippet

Sponsor: Gilead Sciences | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED | Results posted: 2024-04-01